Coronary atherosclerotic plaque intervention with Tongxinluo capsule (TXL-CAP): a multicenter, randomized, double-blind and placebo-controlled study - PubMed
4 hours ago
- #Clinical Trial
- #Coronary Atherosclerosis
- #Traditional Chinese Medicine
- The TXL-CAP study investigated the effects of Tongxinluo capsule (TXL) on coronary plaque stability in patients with acute coronary syndrome.
- This was a multicenter, randomized, double-blind, placebo-controlled clinical trial involving 220 patients with coronary thin-cap lipid-rich plaques detected by OCT.
- Patients were treated with either TXL or placebo for 12 months alongside guideline-directed therapy, including statins.
- Primary endpoint: TXL significantly increased the minimum fibrous cap thickness compared to placebo (115.0 μm vs. 80.0 μm, P < 0.001).
- Secondary outcomes: TXL also showed greater reduction in maximum lipid arc and improved angina symptoms (Seattle Angina Questionnaire and Canadian Cardiovascular Society grading).
- No significant difference in cardiovascular events was observed between the groups at 12 months.
- Conclusion: TXL enhances plaque stability and symptom relief in acute coronary syndrome patients without affecting cardiovascular event rates.